Matches in SemOpenAlex for { <https://semopenalex.org/work/W73365487> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- W73365487 abstract "INTRODUCTION: A relationship between inflammatory response and coagulation is suggested by many observations. In particular, pro-inflammatory cytokines, such as TNFalpha, promote the activation of coagulation and reduce the production of anticoagulant molecules. It is known that inflammatory bowel diseases show a prothrombotic state and a condition of hypercoagulability. Aim of our study was to evaluate whether anti-TNFalpha therapy induces changes in the levels of coagulation activation markers in IBD patients. MATERIALS AND METHODS: We analyzed 48 plasma samples obtained before and 1 hour after 24 infliximab infusions (5 mg/kg) in 9 IBD patients (5 men and 4 women; mean age: 47.6+17.6 years; 4 Crohn's disease, 4 Ulcerative Colitis,1 Indeterminate Colitis). F1+2 and D-dymer levels were measured in each sample using ELISA methods.The data were statistically analyzed by means of Wilcoxon matched paired test. RESULTS: Median F1+2 levels were markdely reduced 1 hour after anti-TNFα infusion (median pre-infusion levels were 247.0 pmol/L and median post-infusion levels were 185.3 pmol/L) (p<0.002). Median D-dymer levels were also significantly reduced, from 485.2 ng/mL to 427.6 ng/mL (p< 0.001). These modifications were more evident in patients naive for infliximab therapy (p<0.02 for F1+2 and p<0.02 for D-dymer) and in Crohn's disease compared with Ulcerative Colitis patients (p=0.01 for F1+2 and p<0.007 for D-dymer).CONCLUSIONS: Infusion of infliximab significantly reduces the activation of coagulation cascade in IBD patients. This effect is early enough to suggest a direct effect of infliximab on the coagulation cascade and a possible new anti-inflammatory mechanism of action of this molecule." @default.
- W73365487 created "2016-06-24" @default.
- W73365487 creator A5056897300 @default.
- W73365487 date "2008-06-23" @default.
- W73365487 modified "2023-09-24" @default.
- W73365487 title "Variazione dei markers di attivata coagulazione indotta dalla terapia infusionale con Infliximab in pazienti affetti da malattie infiammatorie croniche intestinali" @default.
- W73365487 doi "https://doi.org/10.6092/unibo/amsdottorato/707" @default.
- W73365487 hasPublicationYear "2008" @default.
- W73365487 type Work @default.
- W73365487 sameAs 73365487 @default.
- W73365487 citedByCount "0" @default.
- W73365487 crossrefType "dissertation" @default.
- W73365487 hasAuthorship W73365487A5056897300 @default.
- W73365487 hasConcept C126322002 @default.
- W73365487 hasConcept C17991360 @default.
- W73365487 hasConcept C2777138892 @default.
- W73365487 hasConcept C2778260677 @default.
- W73365487 hasConcept C2778382381 @default.
- W73365487 hasConcept C2779134260 @default.
- W73365487 hasConcept C2780479503 @default.
- W73365487 hasConcept C71924100 @default.
- W73365487 hasConcept C90924648 @default.
- W73365487 hasConceptScore W73365487C126322002 @default.
- W73365487 hasConceptScore W73365487C17991360 @default.
- W73365487 hasConceptScore W73365487C2777138892 @default.
- W73365487 hasConceptScore W73365487C2778260677 @default.
- W73365487 hasConceptScore W73365487C2778382381 @default.
- W73365487 hasConceptScore W73365487C2779134260 @default.
- W73365487 hasConceptScore W73365487C2780479503 @default.
- W73365487 hasConceptScore W73365487C71924100 @default.
- W73365487 hasConceptScore W73365487C90924648 @default.
- W73365487 hasLocation W733654871 @default.
- W73365487 hasOpenAccess W73365487 @default.
- W73365487 hasPrimaryLocation W733654871 @default.
- W73365487 isParatext "false" @default.
- W73365487 isRetracted "false" @default.
- W73365487 magId "73365487" @default.
- W73365487 workType "dissertation" @default.